Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study.
Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11-78) were treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of 5 (range: 2-7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12 patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden.
Rutkowski
S
S
Department of Pediatric Oncology, Children's Hospital, University of Wuerzburg, Josef-Schneider-Str. 2, D-97080 Wuerzburg, Germany.
De Vleeschouwer
S
S
Kaempgen
E
E
Wolff
J E A
JE
Kühl
J
J
Demaerel
P
P
Warmuth-Metz
M
M
Flamen
P
P
Van Calenbergh
F
F
Plets
C
C
Sörensen
N
N
Opitz
A
A
Van Gool
S W
SW
D000276:Adjuvants, Immunologic; D000293:Adolescent; D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D001929:Brain Edema / Q000209:etiology; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology*; D005240:Feasibility Studies; D005260:Female; D005909:Glioblastoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D006968:Hypersensitivity, Delayed; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D014611:Vaccination
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines